Key result
Drug-eluting stents showed similar rates of in-hospital mortality or ischemic cardiac events compared to bare-metal stents in patients undergoing subsequent noncardiac surgery (14.6% vs 13.3%; P=0.3).
Why the study?
Does drug-eluting stent compared to bare-metal stent affect in-hospital mortality or ischemic cardiac events in patients undergoing noncardiac surgery?
Population
1953 patients who received drug-eluting or bare-metal stents between April 2003 and March 2007 and…
Comparison
Drug-eluting stent (n=570) vs Bare-metal stents only (n=1383)
Design
Cohort
Follow-up
in-hospital (perioperative)
Authors
Loading...
Similar perioperative events with either stent type should not yet change selection practice; leaves open optimal choice in patients anticipating noncardiac surgery.
Cohort (n=1,953)
Yes
Does drug-eluting stent compared to bare-metal stent affect in-hospital mortality or ischemic cardiac events in patients undergoing noncardiac surgery?
Absolute Event Rate: 14.6% vs 13.3%
p-value: p=0.3
In patients undergoing noncardiac surgery after recent coronary stent implantation, cardiac outcomes are similar for both drug-eluting and bare-metal stents, with the highest risk occurring when surgery is performed within 42 days of implantation.
Cruden et al. (2010) conducted a cohort in Previous coronary stent implantation undergoing noncardiac surgery (n=1,953). Drug-eluting stents vs. Bare-metal stents was evaluated on in-hospital mortality or ischemic cardiac events (p=0.3). Drug-eluting stents showed similar rates of in-hospital mortality or ischemic cardiac events compared to bare-metal stents in patients undergoing subsequent noncardiac surgery (14.6% vs 13.3%; P=0.3).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: